Date: 10/1/2003
Sponsor: Millenium Pharmaceuticals Inc.
Institution: Dana-Farber Cancer Institute and affiliated WMCTG sites in the USA and UK
Physician: Dr. Steven Treon

This Phase II study, chaired by Dr. Treon will be open to WM pts who require therapy and are no longer responding to at least one first line therapy. Patients will receive up to 8 cycles of therapy with Velcade in this study, depending on their response and side effects encountered. As part of these studies, we will also be conducting scientific corollary studies to delineate the mechanisms by which Velcade functions. Endpoints in this study will be: Overall response rates and durations of response.